Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Sölkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M. Eur J Cancer. 2023 Feb;180:108-116. doi: 10.1016/j.ejca.2022.12.003. Epub 2022 Dec 10.

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.

Oleshko, O; Werwitzke, S; Klingberg, A; Witte, T; Eichler, H; Klamroth, R; Holstein, K; Hart, C; Pfrepper, C; Knoebl, P; Greil, R; Neumeister, P; Reipert, BM; Tiede, A. Blood Adv.2023 Jan 10;7(1):122-130. doi: 10.1182/bloodadvances.2022008071.

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.

Wagner, SM; Magnes, T; Melchardt, T; Kiem, D; Weiss, L; Neureiter, D; Wag-ner, C; Aretin, MB; Nemec, S; Gamerith, G; Pall, G; Greil, R; Fuereder, T. Anticancer Res.2023 Mar;43(3):1273-1282. doi: 10.21873/anticanres.16274.

Transcriptomic Profiling Identifies CD8(+ )T Cells in the Brain of Aged and Alzheimer?s Disease Transgenic Mice as Tissue-Resident Memory T Cells.

Altendorfer, B; Unger, MS; Poupardin, R; Hoog, A; Asslaber, D; Gratz, IK; Mrowetz, H; Benedetti, A; de Sousa, DMB; Greil, R; Egle, A; Gate, D; Wyss-Coray, T; Aigner, L. J Immunol. 2022 Oct 1;209(7):1272-1285. doi: 10.4049/jimmunol.2100737. Epub 2022 Aug 31.

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordi-nated by the AGMT Study Group.

Gampenrieder, SP; Dezentjé, V; Lambertini, M; de Nonneville, A; Marhold, M; Le Du, F; Cortés Salgado, A; Alpuim Costa, D; Vaz Batista, M; Chic Ruché, N; Tinchon, C; Petzer, A; Blondeaux, E; Del Mastro, L; Targato, G; Bertucci, F; Gonçalves, A; Viret, F; Bartsch, R; Mannsbart, C; Deleuze, A; Robert, L; Saa-vedra Serrano, C; Gion Cortés, M; Sampaio-Alves, M; Vitorino, M; Pecen, L; Singer, C; Harbeck, N; Rinnerthaler, G; Greil, R. ESMO Open. 2022 Dec 21;8(1):100747. doi: 10.1016/j.esmoop.2022.100747. Online ahead of print.

How We Treat Localized Rectal Cancer-An Institutional Paradigm for To-tal Neoadjuvant Therapy.

Roeder, F; Gerum, S; Hecht, S; Huemer, F; Jäger, T; Kaufmann, R; Klieser, E; Koch, OO; Neureiter, D; Emmanuel, K; Sedlmayer, F; Greil, R; Weiss, L. Cancers (Basel). 2022 Nov 21;14(22):5709. doi: 10.3390/cancers14225709.

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.

Pleyer, L; Sekeres, MA. Lancet Haematol. 2022 Oct;9(10):e714-e716. doi: 10.1016/S2352-3026(22)00252-6. Epub 2022 Sep 2.

What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view.

Schlick, K; Neumayer, B; Neureiter, D. Expert Rev Gastroenterol Hepatol. 2022 Nov-Dec;16(11-12):1019-1022. doi: 10.1080/17474124.2022.2155633. Epub 2022 Dec 13.

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sa-noyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R. Anticancer Res. 2022 Oct;42(10):4773-4785. doi: 10.21873/anticanres.15982.

The influence of pancreatic regression characteristics on outcome of neoadjuvant treated pancreatic cancer in two Austrian university centres.

Neumayer, B; Neureiter, D; Klieser, E; Huemer, F; Weiss, L; Greil, R; Djanani, A; Oberhuber, G; Schlick, K. Virchows Archiv. 2022; 481(Supplement 1):S135-S135.-34th European Congress of Pathology; 03.-07.09.2022; Basel.